Manni Mohyuddin
@ManniMD1
Followers
13K
Following
9K
Media
892
Statuses
8K
Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.
Salt Lake City, UT
Joined June 2020
For those that just followed me: I tweet about plasma cell disorders. I feel strongly about end-of-life, medical education and calling out what I feel is wrong (such as bad control arms, hype etc) I write educational 🧵occasionally- compiled here👇 https://t.co/7RpUkh02NX
#mmsm
6
34
258
@ManniMD1 @OncologyCompany The survival of the control arm was less than contemporary trials of similar agents, which could be from patient selection, lack of blinding, inadequate subsequent care or other unknown factor, better?
1
2
11
👌🏽👌🏽👌🏽 To say that belantamab does not impair quality of life is ridiculous. It speaks to the imperfection of how we assess and report quality of life. Unfortunate that some obvious truths have to be clearly pointed out this way. @AaronGoodman33
@AaronGoodman33 For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited
6
4
40
@AaronGoodman33 For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited
0
1
18
This is a pervasive problem. Why can’t journals ask for editorials from people who don’t get money from the same company whose drug is being discussed? https://t.co/uYWd95uoWW
0
7
27
特定の製薬企業から顧問料を受けてアドバイザーを務めている人物がNEJMのように臨床医に影響力を持つ雑誌に論説を寄稿することについての警鐘をした文章。薬剤の有用性ばかりが強調されてQOLを損ねる有害事象などが過小評価されかねない、と。／NEJM
NEJM is the best journal in our field. I did expect a more nuanced editorial and was a little disappointed to see this. Belantamab is indeed defying expectations and turning out to be better than expected. However.... ⭐️The fact that quality of life was not reported as being
0
7
22
This study (40 patients each arm) is a good representation of how a small sample size can lead to an unreliable estimate. A PFS difference of 13 months with ixazomib is unlikely to be replicated in phase 3, and inconsistent with what ixa has shown! https://t.co/NXPxBvnXwK
2
7
21
NEJM is the best journal in our field. I did expect a more nuanced editorial and was a little disappointed to see this. Belantamab is indeed defying expectations and turning out to be better than expected. However.... ⭐️The fact that quality of life was not reported as being
5
18
125
Actually, Aaron has many papers/trials too. I am biased, but my favorite paper of his one we wrote together in which we highlighted the epidemic of over-treatment of myeloma and its precursor states. Heres a non paywalled link to it: https://t.co/fmWXPU5uSe
Happy to see this piece on @AaronGoodman33 in @TheLancetHaem. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is! https://t.co/AqZkiDOxEf
0
10
35
Happy to see this piece on @AaronGoodman33 in @TheLancetHaem. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is! https://t.co/AqZkiDOxEf
4
8
114
“I would teach a medical student something and it seemed to trigger a lightbulb in their head, and I thought, I wish someone else had told me about that, so I just started sharing more widely.” Profile: @AaronGoodman33 aka Papa Heme @csoncol @UCSanDiego
https://t.co/NO8et7XRHB
2
13
77
You know when Drug is not blockbuster ( or even close to being that ) when it is keep getting defended in repeated correspondence @TheLancetOncol When the Sun 🌞 shines , do we need torch to see it ? Putting both sides . Readers to choose wisely. Any comments @VPrasadMDMPH
5
12
45
Pair this study with this excellent @JAMAInternalMed perspective on the "too fast" bias where groups separate way faster than biologically plausible this is a dead giveaway groups are not the same despite best efforts to adjust @VPrasadMDMPH
https://t.co/hivdms7XkW
AMAZING!!! The second you whiff semaglutide you immediately have improvement on proxy measures of tobacco use!!! Sarcasm intended since this is a negative outcome - too much confounding Also EHR data cannot speak to smoking cessation Epic fail of peer & editorial review
1
2
13
AMAZING!!! The second you whiff semaglutide you immediately have improvement on proxy measures of tobacco use!!! Sarcasm intended since this is a negative outcome - too much confounding Also EHR data cannot speak to smoking cessation Epic fail of peer & editorial review
4
1
10
“Unethical Cancer Study Designs: Why Clinical Trials Aren’t Always Best for Patients.” https://t.co/5Ph27vWMao
1
5
8
This is an updated results data of BCMA CAR-T and BCMA BsAb with updated data from recent presentations/publications based on few requests I got #mmsm ✅Updated data for Elranatamab looks great ✅In areas with equal access to CAR-T: no role for ide cel ✅Excellent BsAb data
6
24
104
For all the money Elsevier takes from us for open access fees, one would think they would have a better way of standardizing logins across their journals. Which username did I have for which journal?😕🤯
3
0
19
Incredible how fast time flies 6 years ago started the longest and most passionate journey of my life. Today, finally a doctor!!! 🎓 Thanks to every person that has mentored me and shaped my way to see this beautiful career Thanks to every patient that was part of my education
5
2
55
Obviously, patient preference reigns supreme. Many will choose bispecifics after hearing the side effects of cilta-cel, which are unpredictable and scary!
0
0
2
In absence of head to head data, my personal preference on T cell redirecting therapy for triple class refractory off trial: -slow/indolent relapse: Cilta-cel -rapid relapse: Elra Prefer to use talquetamab only after BCMA because it is a very toxic drug that ruins QOL #mmsm
4
4
24
Long term follow up of elranatamab Phase 2 trial n=123 97% triple ref, 42% penta ref Median PFS=17 mo Median OS=24 mo Many still in response at latest follow-up https://t.co/Vpf3I5z5Lj (Goodbye ide-cel 😂) #mmsm
1
16
65